Literature DB >> 9802059

Dexamethasone-induced cytotoxic activity and drug resistance effects in androgen-independent prostate tumor PC-3 cells are mediated by lipocortin 1.

M Carollo1, L Parente, N D'Alessandro.   

Abstract

We have examined the effects that dexamethasone (DEX), alone or in combination with doxorubicin (DOX), cisplatin (CDDP), or etoposide (VP-16), exerts on the growth of the androgen-independent prostate cancer PC-3 cells. DEX exhibited only a limited cytotoxicity (growth inhibition of about 28% or 20% after 24 or 72 h of exposure, respectively, in the range of DEX 10-100 nM) and did not induce apoptosis in the cells. This cytotoxicity of DEX was mimicked by an active peptide (peptide Ac2-26) drawn from the human lipocortin 1 N-terminus region and abrogated by an antibody to human lipocortin 1. Two inhibitors of arachidonic acid metabolism, tenidap and indomethacin, also caused cytotoxicity. The cytotoxic effects of DEX in combination with DOX, CDDP, or VP-16 were antagonistic when the steroid was administered 3 h before or simultaneously with the drugs. Other schedule-dependency experiments further clarified that, at least in the case of the combination with DOX, it is the steroid that desensitizes the cells to the drug. When peptide Ac2-26, tenidap, or indomethacin were tested in combination with DOX, antagonism was also observed. DEX treatment neither modified the ability of the cells to accumulate DOX nor changed their weak expression of P-glycoprotein. PC-3 cells also produce IL-6, which autocrinally stimulates their growth, and whose gene expression may be reduced by glucocorticoids. In the present experiments DEX only slightly decreased the production and secretion of IL-6 by the cells. The present findings suggest that the slight cytotoxic activity and the drug resistance effects of DEX on PC-3 cells are mediated by induction of lipocortin 1 and inhibition of arachidonic acid metabolism, with no relationship to downregulation of IL-6 levels. These findings indicate also that the combination of DEX with conventional chemotherapeutic agents may result in antagonistic antitumor effects.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9802059

Source DB:  PubMed          Journal:  Oncol Res        ISSN: 0965-0407            Impact factor:   5.574


  6 in total

1.  Genes and proteins differentially expressed during in vitro malignant transformation of bovine pancreatic duct cells.

Authors:  R Jesnowski; Dmitri Zubakov; Ralf Faissner; Jörg Ringel; Jörg D Hoheisel; Ralf Lösel; Martina Schnölzer; Matthias Löhr
Journal:  Neoplasia       Date:  2007-02       Impact factor: 5.715

2.  Overexpression of ANXA1 confers independent negative prognostic impact in rectal cancers receiving concurrent chemoradiotherapy.

Authors:  Ming-Jen Sheu; Chien-Feng Li; Ching-Yih Lin; Sung-Wei Lee; Li-Ching Lin; Tzu-Ju Chen; Li-Jung Ma
Journal:  Tumour Biol       Date:  2014-05-09

3.  Ursolic acid, a naturally occurring triterpenoid, demonstrates anticancer activity on human prostate cancer cells.

Authors:  E Kassi; Z Papoutsi; H Pratsinis; N Aligiannis; M Manoussakis; P Moutsatsou
Journal:  J Cancer Res Clin Oncol       Date:  2007-02-15       Impact factor: 4.322

4.  Dexamethasone potentiates the antiangiogenic activity of docetaxel in castration-resistant prostate cancer.

Authors:  C Wilson; P Scullin; J Worthington; A Seaton; P Maxwell; D O'Rourke; P G Johnston; S R McKeown; R H Wilson; J M O'Sullivan; D J J Waugh
Journal:  Br J Cancer       Date:  2008-12-02       Impact factor: 7.640

5.  Classification between normal and tumor tissues based on the pair-wise gene expression ratio.

Authors:  YeeLeng Yap; XueWu Zhang; M T Ling; Xianghong Wang; Y C Wong; Antoine Danchin
Journal:  BMC Cancer       Date:  2004-10-07       Impact factor: 4.430

6.  Comparing structural and transcriptional drug networks reveals signatures of drug activity and toxicity in transcriptional responses.

Authors:  Francesco Napolitano; Sandra Pisonero-Vaquero; Francesco Sirci; Diego Carrella; Diego L Medina; Diego di Bernardo
Journal:  NPJ Syst Biol Appl       Date:  2017-08-25
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.